Less than eight months after being formed as a joint venture between Alnylam Pharmaceuticals Inc. and Isis Pharmaceuticals Inc. to develop microRNA-targeted drugs, Regulus Therapeutics LLC landed its first major pharma collaboration, signing London-based GlaxoSmithKline plc in a potential $600 million inflammatory disease alliance. (BioWorld Today) Read More
